Sinus Dilation Market Growth Opportunities and Forecast by 2027

The sinus dilation market size is estimated to reach US$ 3,859.75 million by 2027 from US$ 1,918.73 million in 2019; it is expected to grow at a CAGR of 9.3% during 2019–2027.

Sinus dilation refers to a minimally invasive surgical procedure performed to reshape anatomy to expand sinus pathways and restore drainage. The procedure utilizes small balloons placed in key places in the nose and sinus, dilated to develop the sinus pathways. The sinus dilation market growth is attributed owing to increasing prevalence of chronic sinusitis, growing number of product approvals, and rising popularity of minimally invasive surgeries. However, risks associated with sinus surgical procedures and low adoption of surgical procedures due to the availability of alternative sinusitis-related drugs may hinder the growth of the market.

Market Insights

Increasing Number of Product Approvals

The incidences of chronic rhinosinusitis (CRS) are rising continuously, affecting one in seven people across the world. Subsequently, it has driven the implementation of long-term medical management and functional endoscopic sinus surgery (FESS). Furthermore, technological developments allow various market players to innovate technically advanced medical devices to treat CRS through minimally invasive procedures efficiently. Balloon sinuplasty is the widely used procedure to treat CRS, and various market leaders are developing balloon sinus dilation devices. With developments in balloon sinuplasty, various regulators are approving medical devices. In the past few years, the US Food and Drug Administration (FDA) approved several devices such as Acclarent Relieva Sinus Balloon Catheter of Acclarent, Inc. (Johnson and Johnson) in August 2005, Entellus FinESS device (Entellus Medical) in June 2008, Entellus XprESS Multi-Sinus Dilation Tool (Entellus Medical) in September 2010, Ventera Sinus Dilation System (Smith & Nephew) in 2012, and NuVEnt Sinus Dilation System (Medtronic plc) in July 2013. Similarly, in recent years, the FDA approved many new devices. For instance, in July 2016, FDA approved Vent-Os Sinus Dilation System (SinuSys Corporation), and in October 2017, Relieva SpinPlus Nav Balloon Sinuplasty System (Acclarent, Inc.) received FDA’s approval. Developments in the medical device sector are enhancing the companies’ product portfolio. Moreover, increasing product approvals are assisting in improving people's health across the world and are eventually leading to sinus dilation market growth.

Published Report - Sinus Dilation Market: Strategic Insights

Product-Based Insights

The global sinus dilation market, based on product, is segmented into endoscopes, balloon sinus dilation devices, sinus stents/implants, and handheld instruments. The balloon sinus dilation devices segment held the largest share in 2019. However, the sinus stents/implants segment is expected to witness the highest growth from 2019 to 2027. Balloon sinus dilation devices have emerged as the most attractive segment due to the benefits associated with it such as lower risk of bleeding, no intended damage or removal of sinus tissues, structures, mucous membranes, and nasal bones or sinus cartilage.

Procedure Type-Based Insights

The global sinus dilation market, based on procedure type, is bifurcated into standalone sinus dilation procedures and hybrid sinus dilation procedures. The standalone sinus dilation procedures held a larger share in 2019. However, the hybrid sinus dilation procedures segment is expected to witness a faster growth from 2019 to 2027. The growth of this segment can be attributed to the benefits offered by standalone sinus dilation procedures such as quick relief and reduction in long-lasting cold symptoms and blocked nose. Moreover, the high adoption of these procedures among geriatric patients due to minimal surgical complications is expected to aid the sinus dilation market.

End User-Based Insights

The global sinus dilation market, based on end user, is segmented into hospitals, ambulatory surgical centers, and ENT clinics. The hospitals segment held the largest share in 2019 and is expected to witness lucrative growth from 2019 to 2027. The growth of the hospital segment can also be attributed due to the rise in the number of surgical procedures performed in these settings and the availability of favorable reimbursement policies. The faster development of healthcare infrastructure facilities and a surge in healthcare spending in developing countries have assisted the growth of the global market.

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the sinus dilation market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. The sinus dilation market share is anticipated to flourish with the development of new innovative products by market players. Some of the companies included in our research scope are Medtronic; Smith & Nephew; Johnson and Johnson Services, Inc.; Stryker Corporation; Intersect ENT, Inc.; Dalent Medical; InnAccel Technologies Pvt Ltd.; Olympus Corporation; SinuSys Corporation; and AED.MD.

Sinus Dilation

Published Report - Sinus Dilation Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Sinus Dilation Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

• In August 2020, Acclarent Inc. received FDA clearance for its Next Generation Balloon Dilation System, an integrated balloon sinuplasty (BSP) and Eustachian tube (ET) dilation device intended to provide a means to access the sinus space within/across nasal and sinus structures
• In June 2016, the FDA expanded the indication for Medtronic’s ($MDT) NuVent sinus dilation balloon to include patients with scarred, granulated or previously surgically altered tissue. The expanded indication was based on a prospective, nonrandomized, nonblinded, single-arm study conducted at multiple sites in the US. While the bulk of these cases are treated with antibiotics, decongestants and saline sprays, some patients must undergo sinus surgery to find relief.
• In October 2016, Pacific specialists are among the first to perform minimally invasive balloon sinuplasty using NuVent 3D-Navigation to open blocked sinus pathways.